Device Trial Radar · NCT03353688
Biomarkers to Guide Directional DBS for Parkinson's Disease
Last checked: Nov 20, 2026Latest source record: Sep 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
31
Actual
Start
Nov 3, 2017
Primary completion
Aug 15, 2022
Study completion Jul 31, 2024
Sponsor
- Lead sponsor
- University of Alabama at BirminghamAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Institutes of Health (NIH); National Institute of Neurological Disorders and Stroke (NINDS)
- First posted
- Nov 27, 2017
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to investigate the clinical efficacy of directional DBS electrode technology and whether electrophysiology biomarkers can predict effective contact segments for chronic therapy.
Conditions
- Parkinson Disease
Interventions
Boston Scientific Vercise PC IPG with directional DBS leadDevice
Deep brain stimulation
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Preoperative Baseline in Movement Disorders Society Unified Parkinson's Disease Rating Scale Part 3 (MDS-UPDRS Part III) "Off" MedicationsTime frame: 2, 4, and 6 months post op
- Treatment Preference Survey Programming Strategy PreferenceTime frame: 4 months post surgery
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.